EUVIMEDEUVIMED entdecken
Systematische ÜbersichtOpen Access

Associations Between Surrogate Markers and Clinical Outcomes for Nononcologic Chronic Disease Treatments

Joshua D Wallach, Samuel Yoon, Harry Doernberg, Laura R Glick, Oriana Ciani, Rod S Taylor, Maryam Mooghali, Reshma Ramachandran, Joseph S Ross

JAMA · 21.05.2024 · 331 (19) · 1646

DOI: 10.1001/jama.2024.4175 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift JAMA, erschienen am 21.05.2024. Verfasst von Joshua D Wallach und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Epidemiology, Rollins School of Public Health, Emory University, Atlanta, Georgia. Hauptthemen laut MEDLINE: Biomarkers, Chronic Disease, Drug Approval. Die Arbeit wurde bisher 55-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAAA NIH HHS, NCATS NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Importance Surrogate markers are increasingly used as primary end points in clinical trials supporting drug approvals.

Objective

To systematically summarize the evidence from meta-analyses, systematic reviews and meta-analyses, and pooled analyses (hereafter, meta-analyses) of clinical trials examining the strength of association between treatment effects measured using surrogate markers and clinical outcomes in nononcologic chronic diseases. Data sources The Food and Drug Administration (FDA) Adult Surrogate Endpoint Table and MEDLINE from inception to March 19, 2023. Study Selection Three reviewers selected meta-analyses of clinical trials; meta-analyses of observational studies were excluded. Data Extraction and Synthesis Two reviewers extracted correlation coefficients, coefficients of determination, slopes, effect estimates, or results from meta-regression analyses between surrogate markers and clinical outcomes. Main Outcomes and Measures Correlation coefficient or coefficient of determination, when reported, was classified as high strength ( r ≥ 0.85 or R 2 ≥ 0.72); primary findings were otherwise summarized.

Results

Thirty-seven surrogate markers listed in FDA’s table and used as primary end points in clinical trials across 32 unique nononcologic chronic diseases were included. For 22 (59%) surrogate markers (21 chronic diseases), no eligible meta-analysis was identified. For 15 (41%) surrogate markers (14 chronic diseases), at least 1 meta-analysis was identified, 54 in total (median per surrogate marker, 2.5; IQR, 1.3-6.0); among these, median number of trials and patients meta-analyzed was 18.5 (IQR, 12.0-43.0) and 90 056 (IQR, 20 109-170 014), respectively. The 54 meta-analyses reported 109 unique surrogate marker–clinical outcome pairs: 59 (54%) reported at least 1 r or R 2 , 10 (17%) of which reported at least 1 classified as high strength, whereas 50 (46%) reported slopes, effect estimates, or results of meta-regression analyses only, 26 (52%) of which reported at least 1 statistically significant result. Conclusions and Relevance Most surrogate markers used as primary end points in clinical trials to support FDA approval of drugs treating nononcologic chronic diseases lacked high-strength evidence of associations with clinical outcomes from published meta-analyses.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

BiomarkersChronic DiseaseDrug ApprovalHumansClinical Trials as TopicMeta-Analysis as TopicTreatment OutcomeUnited States

Substanzen

Biomarkers

Autor:innen und Institutionen

  • Department of Epidemiology, Rollins School of Public Health, Emory University, Atlanta, Georgia.
  • Collaboration for Regulatory Rigor, Integrity, and Transparency, Yale School of Medicine, New Haven, Connecticut.
  • Department of Internal Medicine, Massachusetts General Hospital, Harvard Medical School, Boston.
  • Center for Research on Health and Social Care Management, SDA Bocconi School of Management, Milan, Italy.
  • MRC/CSO Social and Public Health Sciences Unit, School of Health & Wellbeing, University of Glasgow, Glasgow, Scotland, United Kingdom.
  • Robertson Centre for Biostatistics, School of Health & Wellbeing, University of Glasgow, Glasgow, Scotland, United Kingdom.

Förderung

  • NIAAA NIH HHS
  • NCATS NIH HHS

Zitieren

APA

Wallach, J. D., Yoon, S., Doernberg, H., Glick, L. R., Ciani, O., Taylor, R. S., Mooghali, M., Ramachandran, R., & Ross, J. S. (2024). Associations Between Surrogate Markers and Clinical Outcomes for Nononcologic Chronic Disease Treatments. JAMA, 331(19), 1646. https://doi.org/10.1001/jama.2024.4175

Vancouver

Wallach JD, Yoon S, Doernberg H, Glick LR, Ciani O, Taylor RS, et al. Associations Between Surrogate Markers and Clinical Outcomes for Nononcologic Chronic Disease Treatments. JAMA. 2024;331(19):1646. doi:10.1001/jama.2024.4175

BibTeX
@article{Wallach2024,
  author = {Wallach, Joshua D and Yoon, Samuel and Doernberg, Harry and Glick, Laura R and Ciani, Oriana and Taylor, Rod S and Mooghali, Maryam and Ramachandran, Reshma and Ross, Joseph S},
  title = {Associations Between Surrogate Markers and Clinical Outcomes for Nononcologic Chronic Disease Treatments},
  journal = {JAMA},
  year = {2024},
  volume = {331},
  number = {19},
  pages = {1646},
  doi = {10.1001/jama.2024.4175}
}
Kostenlos starten →